SW
ALDX icon

SlateStone Wealth’s Aldeyra Therapeutics ALDX Stock Holding History

SlateStone Wealth’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,964
Closed -$48K – 186
2022
Q2 		$48K Hold
11,964
– – 0.01% 181
2022
Q1 		$53K Hold
11,964
– – 0.01% 180
2021
Q4 		$48K Hold
11,964
– – 0.01% 175
2021
Q3 		$105K Hold
11,964
– – 0.02% 165
2021
Q2 		$136K Hold
11,964
– – 0.03% 165
2021
Q1 		$142K Hold
11,964
– – 0.04% 159
2020
Q4 		$82K Hold
11,964
– – 0.02% 168
2020
Q3 		$89K Hold
11,964
– – 0.02% 172
2020
Q2 		$50K Hold
11,964
– – 0.01% 170
2020
Q1 		$30K Hold
11,964
– – 0.01% 170
2019
Q4 		$70K Buy
+11,964
New +$69.1K 0.02% 209

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

SlateStone Wealth's ALDX Position: Q3 2022 in Review

SlateStone Wealth sold out of Aldeyra Therapeutics (ALDX) in Q3 2022, closing a stake of 11,964 shares — an estimated $48K sold.

SlateStone Wealth first reported a position in ALDX in Q4 2019 and held it in 11 quarters. The position peaked at $142K in Q1 2021. 89 funds tracked by Wall St. Rank hold ALDX as of Q3 2022.

  • SlateStone Wealth reported no remaining Aldeyra Therapeutics position as of Q3 2022 after selling out during the quarter.
  • SlateStone Wealth sold 11,964 Aldeyra Therapeutics shares in Q3 2022, an estimated $48K.
  • SlateStone Wealth first reported a position in Aldeyra Therapeutics in Q4 2019 and held it in 11 quarters.
  • SlateStone Wealth's Aldeyra Therapeutics position peaked at $142K in Q1 2021.
  • 89 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2022.

Based on SlateStone Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.